

MARKET ANNOUNCEMENT

USCOM can replace cardiac catheters in children:

LA Children's and University of Southern California Study

SYDNEY, Australia, Monday 9th November 2015: Uscom Limited (ASX code: UCM) (the **Company** or **Uscom**), a cardiovascular and pulmonary medical devices company, today announced to the market the publication of a double blinded, prospective, observational study confirming the accuracy of the USCOM 1A compared to invasive catheter measurements; the current gold standard technology. The study was performed by medical researchers from the prestigious Children's Hospital, Los Angeles and the Keck School of Medicine, University of Southern California.

The study of 31 children aged 9 months to 19 years, is the first to validate the non-invasive USCOM 1A as a replacement technology for the invasive pulmonary artery catheter (PAC) in children. The mean measures by each method differed by less than 5% while the mean error was 11%, well inside the acceptable error which was determined a priori to be 30%.

The PAC procedure requires anaesthesia, cardiac catheterisation, can take up to 2 hours to perform, and is associated with a significant risk of infection and death. USCOM is entirely non-invasive and causes less distress to children than a simple blood pressure reading, takes 5 to 10minutes per measure and is entirely safe.

The USCOM 1A technology is a recommended standard of care in the Pediatric Sepsis Guidelines for measurement of cardiovascular function and implementation of advanced haemodynamics.

Executive Chairman of Uscom, Associate Professor Rob Phillips said, "USCOM is already routine management in leading pediatric intensive care units worldwide, and is being used to save children's lives. This study provides the evidence necessary for widespread adoption of the USCOM 1A in pediatric critical care medicine and cardiology, and supports its replacement of the PAC, and other less accurate methods more generally.

Uscom is a Company based on innovative, practice leading science, and improving the care of children has always been a core objective for us. This study is another measure of our scientific success, and is further evidence of the fundamental and long term social and commercial value of our technologies."

Uscom manufactures and markets the USCOM 1A, the Uscom BP+, and the Uscom Thor digital ultrasonic spirometry technologies. These premium digital devices are changing the way we diagnose and treat cardiovascular and pulmonary diseases, including hypertension, heart failure, asthma, COPD and sleep disorders. The products are integral for optimising management of sepsis and guidance of fluid, inotropes and vasoactive therapies in critical care monitoring, and clinical and home care.

References:

Beltramo F, Menteer J, Razavi A, Khemani RG, Szmuszkovic J, Newth CJL, Ross PA. Validation of an ultrasound cardiac output monitor as a bedside tool for pediatric patients. Ped Cardiol 2015, DOI 10.1007/s00246-015-1261-y

Deep A, Goonasekera CDA, Wang Y, Brierley J. Evolution of haemodynamics and outcome of fluid refractory septic shock in children. Int Care Med 2013 DOI 10.1007/s00134-013-3003-z.

Brierley J, Carcillo J, Choong K, et al. 2007 American College of Critical Care Medicine clinical practice parameters for hemodynamic support of pediatric and neonatal septic shock* Crit Care Med. 2009; 37(2):666-688



MARKET ANNOUNCEMENT

About Uscom

Uscom Limited (UCM) is an ASX listed innovative medical technology company specialising in development and marketing of premium cardiovascular and pulmonary medical devices. Uscom has three practice leading suites of devices in the field of cardiac, vascular and pulmonary monitoring; the USCOM 1A, Uscom BP+ and the Uscom Thor Spirometers. All Uscom devices are premium quality, and deploy innovative and practice leading technologies with FDA, CE and TGA regulatory approval, and which are currently being marketed into global distribution networks.

The USCOM 1A is a simple to use, cost-effective and non-invasive advanced haemodynamic monitor that measures cardiovascular function, detects irregularities and is used to guide treatment. The USCOM 1A device has major applications in Paediatrics, Emergency, Intensive Care Medicine and Anaesthesia, and is the device of choice for management of adult and paediatric sepsis, hypertension, heart failure and for the guidance of fluid, inotrope and vasoactive cardiovascular therapy.

The Uscom BP+ is a supra systolic oscillometric Central Blood Pressure monitor which measures blood pressure and blood pressure waveforms only previously available using cardiac catheterisation. The Uscom BP+ replaces conventional and more widespread sub systolic blood pressure monitors, and is the emerging standard of care measurement in hypertension, heart failure and vascular health. The Uscom BP+ provides a highly accurate and repeatable measurement of central and brachial blood pressure and pulse pressure waveforms using a familiar upper arm cuff. The BP+ is simple to use and requires no complex training with applications in hypertension, heart failure, intensive care, general practice and home care.

Uscom Thor spirometers are high fidelity, digital, pulmonary function testing devices based on multi path ultrasound technology. They are simple and accurate to use and provide advanced pulmonary function testing in small hand held devices that can be used in research, clinical and home care environments. The devices are specialised for assessment of COPD, sleep disordered breathing, asthma and monitoring pulmonary therapeutic compliance.

For more information, please visit: www.uscom.com.au

Uscom Contacts

Associate Professor Rob Phillips Executive Chairman rob@uscom.com.au Catherine Officer Company Secretary secretary@uscom.com.au